EXPLANATORY NOTE
This Amendment No. 1 (the “Amendment”) amends the definitive proxy statement furnished in connection with the solicitation of proxies by the Board of Directors of Firefly Neuroscience, Inc. (the “Company”), filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 3, 2025 (the “Proxy Statement”). The Proxy Statement was filed in connection with the Company’s 2025 Annual Meeting of Stockholders to be held on October 27, 2025, including any adjournment or postponement thereof (the “Annual Meeting”).
Proposal 4 has been revised in this Amendment to present a single, fixed-number increase to the Company’s authorized shares, as set forth in the Certificate of Amendment. All prior references to a “range” of authorized shares or to the Board of Directors’ discretion to determine the final number of authorized shares have been removed. This change has been made to ensure compliance with Delaware General Corporation Law. Accordingly, stockholders are now being asked to approve a specific increase in the number of authorized shares, and the Board will not have discretion to select a number within a range.
This Amendment also clarifies that Proposal 4 is considered a “routine” matter under applicable rules, and not a “non-routine” matter, and conforms the disclosure throughout the Proxy Statement and this Amendment to reflect that brokers, banks, trustees, or other nominees may exercise discretionary voting authority on Proposal 4 in the absence of voting instructions from beneficial owners. In addition, this Amendment revises and harmonizes the disclosure regarding the treatment of abstentions and broker non-votes for Proposals 3 and 4, specifying that, for Proposal 4, abstentions and broker non-votes will have no effect on the outcome of the vote, and for Proposal 3, abstentions and broker non-votes will likewise have no effect on the outcome of the vote.
This Amendment should be read in conjunction with the Proxy Statement.
If you have already returned your proxy card or provided voting instructions, you do not need to take any action unless you wish to change your vote. If you wish to change your vote, you can revoke your proxy or change your vote by following the instructions of the section titled “May I Change or Revoke My Proxy?” on page 4 of the Proxy Statement.
AMENDMENT TO PROXY STATEMENT
The following disclosure amends and restates the paragraph numbered with “(4)” under the heading “NOTICE OF ANNUAL MEETING OF STOCKHOLDERS to be held on October 27, 2025” on the cover page of the Proxy Statement as follows:
To approve Certificate of Amendment No. 1 of Amended and Restated Certificate of Incorporation of Firefly Neuroscience, Inc. (the “Certificate of Amendment”) to increase the total number of authorized shares from 101,000,000 to 5,001,000,000, consisting of (i) 5,000,000,000 shares of Common Stock, par value $0.0001 per share, and (ii) 1,000,000 shares of Preferred Stock, par value $0.0001 per share (“Proposal 4”); and
The following disclosure amends and restates the paragraph numbered with “(4)” under the heading “IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER ANNUAL MEETING TO BE HELD ON MONDAY, OCTOBER 27, 2025” on the cover page of the Proxy Statement as follows:
To approve Certificate of Amendment No. 1 of Amended and Restated Certificate of Incorporation of Firefly Neuroscience, Inc. (the “Certificate of Amendment”) to increase the total number of authorized shares from 101,000,000 to 5,001,000,000, consisting of (i) 5,000,000,000 shares of Common Stock, par value $0.0001 per share, and (ii) 1,000,000 shares of Preferred Stock, par value $0.0001 per share; and
The following disclosure amends and restates the heading “PROPOSAL 4 TO APPROVE THE BOARD’S DISCRETION TO IMPLEMENT ONE OR MORE AMENDMENTS TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FIREFLY NEUROSCIENCE, INC.” in the TABLE OF CONTENTS on page i of the Proxy Statement as follows:
PROPOSAL 4 TO APPROVE CERTIFICATE OF AMENDMENT NO. 1 TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FIREFLY NEUROSCIENCE, INC.